Timber Pharmaceuticals Inc

ASE:TMBR   3:57:03 PM EDT
0.92
+0.03 (+2.94%)
Products

Timber Pharmaceuticals Announces Last Patient Last Visit In Phase 2B Control Study Evaluating Tmb-001 In Moderate To Severe Congenital Ichthyosis

Published: 08/24/2021 15:04 GMT
Timber Pharmaceuticals Inc (TMBR) - Timber Pharmaceuticals Announces Last Patient Last Visit in Phase 2b Control Study Evaluating Tmb-001 in Moderate to Severe Congenital Ichthyosis.
Timber Pharmaceuticals Inc - Topline Results From Phase 2b Control Study Evaluating Tmb-001 Expected to Be Announced in Q4 of 2021.
Timber Pharmaceuticals Inc - Company Preparing for an End-of-phase 2 Meeting With FDA.